PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy

Clinicopathological prognostic features have limited value to identify with precision newly diagnosed patients with hormone receptor (HR)-positive, HER2-negative breast cancer (BC), who would benefit from chemotherapy (CT) in addition to adjuvant hormonal therapy (HT). The 21-gene Oncotype DX Breast...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:NPJ Breast Cancer
Autors principals: Cognetti, Francesco, Masetti, Riccardo, Fabi, Alessandra, Bianchi, Giulia, Santini, Donatella, Rognone, Alessia, Catania, Giovanna, Angelucci, Domenico, Naso, Giuseppe, Giuliano, Mario, Vassalli, Lucia, Vici, Patrizia, Scognamiglio, Giovanni, Generali, Daniele, Zambelli, Alberto, Colleoni, Marco, Tinterri, Corrado, Scanzi, Francesco, Vigna, Leonardo, Scavina, Paola, Gamucci, Teresa, Marrazzo, Emilia, Scinto, Angelo Fedele, Berardi, Rossana, Fabbri, Maria Agnese, Pinotti, Graziella, Franco, Daniela, Terribile, Daniela Andreina, Tonini, Giuseppe, Cianniello, Daniela, Barni, Sandro
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8099872/
https://ncbi.nlm.nih.gov/pubmed/33953182
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41523-021-00246-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars